Search

Your search keyword '"Packard, C"' showing total 3 results
Start Over Author "Packard, C" Publication Year Range Last 3 years
3 results on '"Packard, C"'

1. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation

Author

Kaptoge, S, Seshasai, SRK, Sun, L, Walker, M, Bolton, T, Spackman, S, Ataklte, F, Willeit, P, Bell, S, Burgess, S, Pennells, L, Altay, S, Assmann, G, Ben-Shlomo, Y, Best, LG, Björkelund, C, Blazer, DG, Brenner, H, Brunner, EJ, Dagenais, GR, Cooper, JA, Cooper, C, Crespo, CJ, Cushman, M, D'Agostino, RB, Sr, Daimon, M, Daniels, LB, Danker, R, Davidson, KW, de Jongh, RT, Donfrancesco, C, Ducimetiere, P, Elders, PJM, Engström, G, Ford, I, Gallacher, I, Bakker, SJL, Goldbourt, U, de La Cámara, G, Grimsgaard, S, Gudnason, V, Hansson, PO, Imano, H, Jukema, JW, Kabrhel, C, Kauhanen, J, Kavousi, M, Kiechl, S, Knuiman, MW, Kromhout, D, Krumholz, HM, Kuller, LH, Laatikainen, T, Lowler, DA, Meyer, HE, Mukamal, K, Nietert, PJ, Ninomiya, T, Nitsch, D, Nordestgaard, BG, Palmieri, L, Price, JF, Ridker, PM, Sun, Q, Rosengren, A, Roussel, R, Sakurai, M, Salomaa, V, Schöttker, B, Shaw, JE, Strandberg, TE, Sundström, J, Tolonen, H, Tverdal, A, Verschuren, WMM, Völzke, H, Wagenknecht, L, Wallace, RB, Wannamethee, SG, Wareham, NJ, Wassertheil-Smoller, S, Yamagishi, K, Yeap, BB, Harrison, S, Inouye, M, Griffin, S, Butterworth, AS, Wood, AM, Thompson, SG, Sattar, N, Danesh, J, Di Angelantonio, E, Tipping, RW, Russell, S, Johansen, M, Bancks, MP, Mongraw-Chaffin, M, Magliano, D, Barr, ELM, Zimmet, PZ, Whincup, PH, Willeit, J, Leitner, C, Lawlor, DA, Elwood, P, Sutherland, SE, Hunt, KJ, Selmer, RM, Haheim, LL, Ariansen, I, Tybjaer-Hansen, A, Frikkle-Schmidt, R, Langsted, A, Lo Noce, C, Balkau, B, Bonnet, F, Fumeron, F, Pablos, DL, Ferro, CR, Morales, TG, Mclachlan, S, Guralnik, J, Khaw, KT, Holleczek, B, Stocker, H, Nissinen, A, Vartiainen, E, Jousilahti, P, Harald, K, Massaro, JM, Pencina, M, Lyass, A, Susa, S, Oizumi, T, Kayama, T, Chetrit, A, Roth, J, Orenstein, L, Welin, L, Svärdsudd, K, Lissner, L, Hange, D, Mehlig, K, Tilvis, RS, Dennison, E, Westbury, L, Norman, PE, Almeida, OP, Hankey, GJ, Hata, J, Shibata, M, Furuta, Y, Bom, MT, Rutters, F, Muilwijk, M, Kraft, P, Lindstrom, S, Turman, C, Kiyama, M, Kitamura, A, Gerber, Y, Salonen, JT, van Schoor, LN, van Zutphen, EM, Melander, O, Psaty, BM, Blaha, M, de Boer, IH, Kronmal, RA, Grandits, G, Shin, H-C, Albertorio, JR, Gillum, RF, Hu, FB, Humphries, S, Hill- Briggs, F, Vrany, E, Butler, M, Schwartz, JE, Iso, H, Amouyel, P, Arveiler, D, Ferrieres, J, Gansevoort, RT, de Boer, R, Kieneker, L, Trompet, S, Kearney, P, Cantin, B, Després, JP, Lamarche, B, Laughlin, G, McEvoy, L, Aspelund, T, Thorsson, B, Sigurdsson, G, Tilly, M, Ikram, MA, Dorr, M, Schipf, S, Fretts, AM, Umans, JG, Ali, T, Shara, N, Davey-Smith, G, Can, G, Yüksel, H, Özkan, U, Nakagawa, H, Morikawa, Y, Ishizaki, M, Njølstad, I, Wilsgaard, T, Mathiesen, E, Buring, J, Cook, N, Arndt, V, Rothenbacher, D, Manson, J, Tinker, L, Shipley, M, Tabak, AG, Kivimaki, M, Packard, C, Robertson, M, Feskens, E, and Geleijnse, M

Published
2023
Full Text
View/download PDF

2. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.

Author

Hageman SHJ, Kaptoge S, de Vries TI, Lu W, Kist JM, van Os HJA, Numans ME, Läll K, Bobak M, Pikhart H, Kubinova R, Malyutina S, Pająk A, Tamosiunas A, Erbel R, Stang A, Schmidt B, Schramm S, Bolton TR, Spackman S, Bakker SJL, Blaha M, Boer JMA, Bonnefond A, Brenner H, Brunner EJ, Cook NR, Davidson K, Dennison E, Donfrancesco C, Dörr M, Floyd JS, Ford I, Fu M, Gansevoort RT, Giampaoli S, Gillum RF, Gómez-de-la-Cámara A, Håheim LL, Hansson PO, Harms P, Humphries SE, Ikram MK, Jukema JW, Kavousi M, Kiechl S, Kucharska-Newton A, Pablos DL, Matsushita K, Meyer HE, Moons KGM, Mortensen MB, Muilwijk M, Nordestgaard BG, Packard C, Pamieri L, Panagiotakos D, Peters A, Potier L, Providencia R, Psaty BM, Ridker PM, Rodriguez B, Rosengren A, Sattar N, Schöttker B, Schwartz JE, Shea S, Shipley MJ, Sofat R, Thorand B, Verschuren WMM, Völzke H, Wareham NJ, Westbury L, Willeit P, Zhou B, Danesh J, Visseren FLJ, Di Angelantonio E, Pennells L, and Dorresteijn JAN

Subjects
Humans, Risk Assessment, Female, Male, Europe epidemiology, Middle Aged, Aged, Adult, Time Factors, Decision Support Techniques, Prognosis, Risk Factors, Cardiovascular Diseases prevention & control, Cardiovascular Diseases epidemiology, Heart Disease Risk Factors
Abstract

Aims: The 2021 European Society of Cardiology prevention guidelines recommend the use of (lifetime) risk prediction models to aid decisions regarding initiation of prevention. We aimed to update and systematically recalibrate the LIFEtime-perspective CardioVascular Disease (LIFE-CVD) model to four European risk regions for the estimation of lifetime CVD risk for apparently healthy individuals., Methods and Results: The updated LIFE-CVD (i.e. LIFE-CVD2) models were derived using individual participant data from 44 cohorts in 13 countries (687 135 individuals without established CVD, 30 939 CVD events in median 10.7 years of follow-up). LIFE-CVD2 uses sex-specific functions to estimate the lifetime risk of fatal and non-fatal CVD events with adjustment for the competing risk of non-CVD death and is systematically recalibrated to four distinct European risk regions. The updated models showed good discrimination in external validation among 1 657 707 individuals (61 311 CVD events) from eight additional European cohorts in seven countries, with a pooled C-index of 0.795 (95% confidence interval 0.767-0.822). Predicted and observed CVD event risks were well calibrated in population-wide electronic health records data in the UK (Clinical Practice Research Datalink) and the Netherlands (Extramural LUMC Academic Network). When using LIFE-CVD2 to estimate potential gain in CVD-free life expectancy from preventive therapy, projections varied by risk region reflecting important regional differences in absolute lifetime risk. For example, a 50-year-old smoking woman with a systolic blood pressure (SBP) of 140 mmHg was estimated to gain 0.9 years in the low-risk region vs. 1.6 years in the very high-risk region from lifelong 10 mmHg SBP reduction. The benefit of smoking cessation for this individual ranged from 3.6 years in the low-risk region to 4.8 years in the very high-risk region., Conclusion: By taking into account geographical differences in CVD incidence using contemporary representative data sources, the recalibrated LIFE-CVD2 model provides a more accurate tool for the prediction of lifetime risk and CVD-free life expectancy for individuals without previous CVD, facilitating shared decision-making for cardiovascular prevention as recommended by 2021 European guidelines., Competing Interests: Conflict of interest: Due to the very long author list, these will be provided per author using ICMJE forms at the revision stage, if applicable., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

3. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.

Author

Mach F, Visseren FLJ, Cater NB, Salhi N, Soronen J, Ray KK, Delgado V, Jukema JW, Laufs U, Zamorano JL, Ros E, Plat J, Gesztes AG, Tokgozoglu L, Packard C, and Libby P

Subjects
Humans, Europe, Risk Factors, Societies, Medical, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Dyslipidemias drug therapy, Cardiovascular Diseases drug therapy, Cardiovascular Diseases prevention & control
Abstract

Cardiovascular (CV) disease is the most common cause of death in Europe. Despite proven benefits, use of lipid-lowering therapy remains suboptimal. Treatment goals are often not achieved, even in patients at high risk with atherosclerotic CV disease (ASCVD). The occurrence of CV events in patients on lipid-lowering drugs is defined as "residual risk", and can result from inadequate control of plasma lipids or blood pressure, inflammation, diabetes, and environmental hazards. Assessment of CV risk factors and vascular imaging can aid in the evaluation and management decisions for individual patients. Lifestyle measures remain the primary intervention for lowering CV risk. Where drug therapies are required to reach lipid treatment targets, their effectiveness increases when they are combined with lifestyle measures delivered through formal programs. However, lipid drug dosage and poor adherence to treatment remain major obstacles to event-free survival. This article discusses guideline-supported treatment algorithms beyond statin therapy that can help reduce residual risk in specific patient profiles while also likely resulting in substantial healthcare savings through better patient management and treatment adherence., Competing Interests: Declaration of competing interest Mach: Research grants from Amgen, Daiichi-Sankyo, Novartis, and Sanofi; participation on a data safety monitoring board or advisory board for Amgen, Daiichi-Sankyo, Novartis, and Sanofi. Visseren: None. Cater: Employment with and stock or stock options from Pfizer. Salhi: Employment with and stock or stock options from Amgen. Soronen: Employment with and stock or stock options from Daiichi Sankyo. Ray: Unrestricted institutional research grants from Amgen, Daiichi-Sankyo, Regeneron, and Sanofi; consulting fees for participation in a steering committee, executive committee, or advisory board for Novartis, Esperion, Daiichi Sankyo, Abbott, Bayer, Eli Lilly, Silence Therapeutics, CSL Behring, New Amsterdam Pharma, Sanofi, Amgen, Novo Nordisk, Boehringer Ingelheim, Scribe, Vaxxinity, CRISPR, AstraZeneca, Kowa Pharmaceuticals, Cargene Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for CME and non-CME materials from Novartis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo, Amgen, Sanofi; leadership role (President) of European Atherosclerosis Society (EAS); and stock or stock options from Pemi-31 Therapeutics. Delgado: Consulting fees from Edwards Lifesciences, Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott Vascular, Edwards Lifescience, GE Healthcare, Medtronic, Novartis, and Philips. Jukema: Research grants from and/or was speaker (with or without lecture fees) on CME accredited meetings sponsored by Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi-Sankyo, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute, and the European Community Framework KP7 Programme. Laufs: Support for the present manuscript from the European Society of Cardiology (ESC); grants or contracts from Amgen, Daiichi-Sankyo, and Novartis; consulting fees from Amgen, Boehringer Ingelheim, Daiichi-Sankyo, and Novartis; payment for public lectures from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Novo Nordisk, Pfizer, and Sanofi; leadership roles with ESC, DGK, DACH, and EAS. Zamorano: Grants or contracts from Abbott and Edwards Lifesciences; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bayer, Amgen, Daiichi-Sankyo, and Pfizer. Ros: Honoraria for a lecture at the Sociedad Española de Arteriosclerosis (SEA), for participation in an EAS Task Force Expert Panel on Dyslipidaemia Guidelines, for manuscript writing for the California Walnut Commission, and for participation in an educational seminar for the Fundación Dieta Mediterránea; and participation on an advisory board for Alexion. Plat: Travel reimbursement for the meeting relating to the present manuscript from the ESC; institutional grants from Raisio to evaluate effects of plant stanol esters on vaccinations; honoraria paid directly to the institution for lectures at the EAS 2020 annual meeting, the EAS 2021 annual meeting, and at the BASF Day of Science Symposium 2022. Gesztes: None. Tokgozoglu: Consulting fees Astra Zeneca, Abbott, Amgen, Bayer, MSD, Mylan, Novartis, Sanofi, Novo Nordisk, and Daiichi-Sankyo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbott, Amgen, Daiichi-Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati, and Janssen; participation on a data safety monitoring board or advisory board for Abbott, Amgen, Novartis, Sanofi, Daiichi-Sankyo, Mylan, and Pfizer; and leadership roles with the EAS (past president) and Turkish Society of Cardiology (past president). Packard: Institutional research grant from Pfizer; consulting fees from Amgen, Amarin, Daiichi-Sankyo, MSD, Novartis, and Response therapeutics; and payment or honoraria for manuscript preparation from Novartis and for lectures for Amgen and Amarin. Libby: Support for the present manuscript from the National Heart, Lung, and Blood Institute (NHLBI) (grant nos. 1R01HL134892, 1R01HL163099-01), the American Heart Association (grant no. 18CSA34080399), the RRM Charitable Fund, and the Simard Fund; payment or honoraria for lectures and educational events from Pri-Med and Medtelligence; Research support from Novartis, Novo Nordisk, and Genentech, a US patent application for the use of canakinumab (application no. 20200239564) and a US provisional patent application for the treatment of brain ischemia-reperfusion injury (application no. 5409-0001); participation on a data safety monitoring board or advisory board for Amgen, Novartis, DalCor, and XBiotech, Inc; a leadership role (Director) for XBiotech, Inc; stock or stock options from XBiotech, Inc, TenSixteen Bio, and Soley Therapeutics; receipt of drugs from Novartis and Regeneron; consultancies (unpaid) for Amgen, Kowa Pharmaceuticals, Medimmune, AstraZeneca, Bain Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Merck, Moderna, Kancera, Novo Nordisk, Pfizer, Sanofi-Regeneron, participation on scientific advisory boards (unpaid) for Amgen, Kowa Pharmaceuticals, Olatec Pharmaceuticals, Medimmune, Caristo, Cartesian, CSL Behring, Dewpoint, Plaquetec, TenSixteen Bio, Soley Therapeutics, and Eulicid., (Copyright © 2024. Published by Elsevier Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results